Trodelvy (sacituzumab govitecan), First-in-class medicine to treat aggressive form of breast cancer
EMA has recommended granting a marketing authorisation in the European Union…
Ibrance, Palbociclib, is the #1 prescribed, FDA-approved oral combination treatment for HR+, HER2- mBC.
IBRANCE® IS THE FIRST FDA-APPROVED MEDICATION in its class. IBRANCE is a…
Tukysa (tucatinib) new option of treatment of adult patients with advanced forms of HER2-positive breast cancer
As part of Project Orbis, the U.S. Food and Drug Administration has approved…
Enhertu (fam-trastuzumab deruxtecan-nxki), new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
The U.S. Food and Drug Administration granted accelerated approval to Enhertu…
Lynparza (olaparib), already licensed for breast and ovarian cancer,it's set to become the world's first precision medicine for prostate cancer.
A new clinical trial founds Lynparza (olaparib), the MSD and AstraZeneca PARP…